Citius Pharmaceuticals Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while ZIM Integrated Shipping Services Ltd trades at $25.24 (market cap $2.96B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 147.9× Citius Pharmaceuticals Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ZIM | |
|---|---|---|
Market Cap | $20.01M | $2.96B |
Sector | Health | Industrials |
52-Week High | $1.82 | $29.27 |
52-Week Low | $0.48 | $12.44 |
Enterprise Value | $16.23M | $6.81B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
ZIM trades at $25.27, up 0.24% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net income of $479.20 million in 2025, but profitability is expected to decline sharply in 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and pressure from lower freight rates.
The outlook is cautious, with analysts evenly split between hold and sell ratings and a consensus price target of $16.75, well below the current price. Key risks include regulatory hurdles for the merger, volatile shipping rates, and declining earnings. Upside depends on successful deal execution or improved operational performance.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →